Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer

Biliary tract cancers (BTCs), for their low incidence, have been often considered together. Gallbladder cancer (GBC) is the most common biliary tract malignancy, characterized by late diagnosis and poor prognosis, and although it is considered a rare tumor in western countries, other areas of the wo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Matteo Canale, Manlio Monti, Ilario Giovanni Rapposelli, Paola Ulivi, Francesco Giulio Sullo, Giulia Bartolini, Elisa Tiberi, Giovanni Luca Frassineti
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	advanced gallbladder cancer molecular characterization targeted therapy immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/16b026a0d3554b54ae9b39c9fb66b95d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:16b026a0d3554b54ae9b39c9fb66b95d
record_format	dspace
spelling	oai:doaj.org-article:16b026a0d3554b54ae9b39c9fb66b95d2021-11-25T17:02:29ZMolecular Targets and Emerging Therapies for Advanced Gallbladder Cancer10.3390/cancers132256712072-6694https://doaj.org/article/16b026a0d3554b54ae9b39c9fb66b95d2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5671https://doaj.org/toc/2072-6694Biliary tract cancers (BTCs), for their low incidence, have been often considered together. Gallbladder cancer (GBC) is the most common biliary tract malignancy, characterized by late diagnosis and poor prognosis, and although it is considered a rare tumor in western countries, other areas of the world show considerable incidence rates. In 2010, results from the large phase III ABC-02 clinical trial on GBC identified the gemcitabine and cisplatin combination as the most effective first-line regimen for both GBC and other BTCs. Since then, various systemic therapies have proven active in BTCs in both first- and second-line settings. Molecular profiling has highlighted important genetic differences between GBC and other BTCs, opening new ways for targeted therapy in advanced disease where standard chemotherapies show marginal benefit. Genome-wide data analysis have shown that GBC molecular landscape offer possible strategies for precision medicine approaches, and a better molecular understanding of the GBC is needed to better stratify patients for treatment. In this review, we discuss the molecular targetable agents for GBC, including the results that emerged by clinical trials exploring new treatment strategies.Matteo CanaleManlio MontiIlario Giovanni RapposelliPaola UliviFrancesco Giulio SulloGiulia BartoliniElisa TiberiGiovanni Luca FrassinetiMDPI AGarticleadvanced gallbladder cancermolecular characterizationtargeted therapyimmunotherapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5671, p 5671 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	advanced gallbladder cancer molecular characterization targeted therapy immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	advanced gallbladder cancer molecular characterization targeted therapy immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Matteo Canale Manlio Monti Ilario Giovanni Rapposelli Paola Ulivi Francesco Giulio Sullo Giulia Bartolini Elisa Tiberi Giovanni Luca Frassineti Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
description	Biliary tract cancers (BTCs), for their low incidence, have been often considered together. Gallbladder cancer (GBC) is the most common biliary tract malignancy, characterized by late diagnosis and poor prognosis, and although it is considered a rare tumor in western countries, other areas of the world show considerable incidence rates. In 2010, results from the large phase III ABC-02 clinical trial on GBC identified the gemcitabine and cisplatin combination as the most effective first-line regimen for both GBC and other BTCs. Since then, various systemic therapies have proven active in BTCs in both first- and second-line settings. Molecular profiling has highlighted important genetic differences between GBC and other BTCs, opening new ways for targeted therapy in advanced disease where standard chemotherapies show marginal benefit. Genome-wide data analysis have shown that GBC molecular landscape offer possible strategies for precision medicine approaches, and a better molecular understanding of the GBC is needed to better stratify patients for treatment. In this review, we discuss the molecular targetable agents for GBC, including the results that emerged by clinical trials exploring new treatment strategies.
format	article
author	Matteo Canale Manlio Monti Ilario Giovanni Rapposelli Paola Ulivi Francesco Giulio Sullo Giulia Bartolini Elisa Tiberi Giovanni Luca Frassineti
author_facet	Matteo Canale Manlio Monti Ilario Giovanni Rapposelli Paola Ulivi Francesco Giulio Sullo Giulia Bartolini Elisa Tiberi Giovanni Luca Frassineti
author_sort	Matteo Canale
title	Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
title_short	Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
title_full	Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
title_fullStr	Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
title_full_unstemmed	Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
title_sort	molecular targets and emerging therapies for advanced gallbladder cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/16b026a0d3554b54ae9b39c9fb66b95d
work_keys_str_mv	AT matteocanale moleculartargetsandemergingtherapiesforadvancedgallbladdercancer AT manliomonti moleculartargetsandemergingtherapiesforadvancedgallbladdercancer AT ilariogiovannirapposelli moleculartargetsandemergingtherapiesforadvancedgallbladdercancer AT paolaulivi moleculartargetsandemergingtherapiesforadvancedgallbladdercancer AT francescogiuliosullo moleculartargetsandemergingtherapiesforadvancedgallbladdercancer AT giuliabartolini moleculartargetsandemergingtherapiesforadvancedgallbladdercancer AT elisatiberi moleculartargetsandemergingtherapiesforadvancedgallbladdercancer AT giovannilucafrassineti moleculartargetsandemergingtherapiesforadvancedgallbladdercancer
_version_	1718412759895375872

Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer

Ejemplares similares